Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 17, 2006, Pages 4686-4691

  Petrov, Kimberly G ^a   Zhang, Yue Mei ^a   Carter, Malcolm ^a   Cockerill, G Stuart ^a   Dickerson, Scott ^a   Gauthier, Cassandra A ^a   Guo, Yu ^a   Mook Jr , Robert A ^a   Rusnak, David W ^a   Walker, Ann L ^a   Wood, Edgar R ^a   Lackey, Karen E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

EGFR kinase inhibitors; ErbB 1 tyrosine kinase inhibitors; ErbB 2 tyrosine kinase inhibitors; Lapatinib; Quinazoline

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; QUINAZOLINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; FURANS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746196584     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.090     Document Type: Article

References (19)

1. YZ: J&J Pharm, 1000 Route 202, Raritan, NJ 08869.
2. GSC & MC: Arrow Therapeutics, Britannia House, 7 Trinity Street, London SE1 1DS, UK.
3. CAG: Array Biopharma, Boulder, CO.
4. Klapper L.N., Kirschbaun M.H., and Yarden Y. Adv. Cancer Res 77 (2000) 25
5. Tiseo M., Loprevite M., and Ardizzoni A. Curr. Med. Chem. 4 (2004) 139
6. Cockerill S.G., and Lackey K.E. Curr. Top. Med. Chem. 2 (2002) 1001
7. Ransom M. Br. J. Cancer 90 (2004) 2250
8. Rusnak D.W., Lackey K.E., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B., Murray D.M., Mullin R.J., Knight W.B., and Gilmer T.M. Mol. Cancer Ther. 1 (2001) 85
9. McClure M.S., Roschangar F., Hodson S.J., Millar A., and Osterhout M.H. Synthesis 11 (2001) 1681
10. McClure M.S., Glover B., McSorley E., Millar A., Osterhout M.H., and Roschangar F. Org. Lett. 3 (2001) 1677
11. Cockerill G.S., Stubberfield C., Stables J., Carter M., Guntrip S., Smith K., McKeown S., Shaw R., Tapley P., Thomson L., Affleck K., Jowett A., Hayes D., Wilson M., Wollard P., and Spalding D. Bioorg. Med. Chem. Lett. 11 (2001) 1401
12. Rusnak D.W., Affleck K., Cockerill S.G., Stubberfield C., Harris R., Page M., Smith K.J., Guntrip S.B., Carter M.C., Shaw R.J., Jowett A., Stables J., Tapley P., Wood E.R., Brignola P.S., Kadwell S.H., Reep B.R., Mullin R.J., Alligood K.J., Keith B.R., Crosby R.M., Murray D.M., Knight W.B., Gilmer T.M., and Lackey K.E. Cancer Res. 61 (2001) 7196
13. Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J. PCT Appl. WO9802434, 1998.
14. Khanna I.K., Weier R.M., Yu Y., Collins P.W., Miyashiro J.M., Koboldt C.M., Veenhuizen A.W., Currie J.L., Seibert K., and Isakson P.C. J. Med. Chem. 40 (1997) 1619
15. Liebowitz S.M., Lombardini J.B., and Allen C.I. Biochem. Pharmacol. 38 (1989) 399
16. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., and Wood E.R. J. Biol. Chem. 277 (2002) 1576
17. Modjtahedi H., Affleck K., Stubberfield C., and Dean C. Int. J. Oncol. 13 (1998) 335
18. Pasleau F., Grooteclaes M., and Gol-Winkler R. Oncogene 8 (1993) 849
19. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., and Shewchuk L.A. Cancer Res. 64 (2004) 6652 PDB ID 1XKK